Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by NACE. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NACE or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

CME/CE Podcast: COPD Inflammation & Exacerbations: Your Questions Answered

12:52
 
Share
 

Manage episode 486840910 series 2878447
Content provided by NACE. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NACE or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/copd-inflammation-exacerbations-your-questions-answered-10143

Summary
Rejoin the conversation on COPD, inflammation, and new and emerging agents as two of our expert faculty come together to answer your top questions. Questions submitted from the recent Conversations in Primary Care live virtual symposia guide the discussion as we dig a bit deeper on type 2 inflammation, changes in COPD management, and new and emerging agents – including recently approved biologic agents – for COPD.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

  • Review the relationship between inflammation, exacerbation, and disease progression in COPD, noting different inflammatory endotypes of patients with COPD
  • Discuss recent evidence surrounding the use of biologic agents in the management of patients with COPD and type 2 inflammation
  • Integrate current guidelines with clinical data on new and emerging agents for the management of COPD, distinguishing patients with and without markers of type 2 inflammation

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

  continue reading

103 episodes

Artwork
iconShare
 
Manage episode 486840910 series 2878447
Content provided by NACE. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NACE or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/copd-inflammation-exacerbations-your-questions-answered-10143

Summary
Rejoin the conversation on COPD, inflammation, and new and emerging agents as two of our expert faculty come together to answer your top questions. Questions submitted from the recent Conversations in Primary Care live virtual symposia guide the discussion as we dig a bit deeper on type 2 inflammation, changes in COPD management, and new and emerging agents – including recently approved biologic agents – for COPD.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

  • Review the relationship between inflammation, exacerbation, and disease progression in COPD, noting different inflammatory endotypes of patients with COPD
  • Discuss recent evidence surrounding the use of biologic agents in the management of patients with COPD and type 2 inflammation
  • Integrate current guidelines with clinical data on new and emerging agents for the management of COPD, distinguishing patients with and without markers of type 2 inflammation

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

  continue reading

103 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play